Led by myself and a digital health VC partner, KELES bridges the gap between start up innovation, international scaling and global impactWe are uniquely positioned to access the best deals, enable scale up and maximize exit opportunities. We’ve sat at every seat around the table; from inception to exit to investor and acquirer, we know the economics and how-to of execution€250m Fund - Ticket Size €8m to €30mKELES Investment Focus: Growth Stage - Demonstrated Profitability - Scaling… Show more Led by myself and a digital health VC partner, KELES bridges the gap between start up innovation, international scaling and global impactWe are uniquely positioned to access the best deals, enable scale up and maximize exit opportunities. We’ve sat at every seat around the table; from inception to exit to investor and acquirer, we know the economics and how-to of execution€250m Fund - Ticket Size €8m to €30mKELES Investment Focus: Growth Stage - Demonstrated Profitability - Scaling Inflection Point3 Core Digital Health Segments: New R&D Model (techbio/digitised trials) - Diagnostics (AI imaging/digital medtech) - Patient Care (acute/chronic)The fund KELES S.C.Sp., SICAV - RAIF is established in Luxembourg, and we have bases in Paris, London and Brussels Show less

Digital Health Business AngelInvest in Seed & Series A

HITLAB, the Digital Health Innovation Lab of Columbia University

Led Sanofi strategy across the whole companyIs one of the architect of 14 acquisitions and accelerated investments across the pipeline with a focus on oncology, immunology, cell & gene therapy, digital healthSet up Sanofi Gene Therapy Unit from scratch from strategy to operations kick off Has been a key orchestrator of stock rising to €104 all time high

Led Sanofi 2030 (company wide strategy) and defined 5/10 year roadmap for new CEO arrival

Reshaped Sanofi China 2030 roadmap to accelerate shift from Primary Care to Specialty Care - Defined Emerging Market and Japan 2030 roadmap

Led initial Dupixent strategy leveraging specialty care launch experience Humira/Kaletra - Led Global Pharma Resources Allocation

Took over Abbott APAC and continued double digit growth ($1.4Bn, 25 countries, 4,000 people)

Tripled sales of Abbott RICC Region in 3 years from $350M to $1Bn, 50% inorganic: launched Humira in China, won Kaletra tender every year in Russia, accelerated EP portfolio growth, integrated Solvay Pharma, RICC recognized as Abbott key growth driver in 2011 results

Led Abbott HCV pipeline development (2 assets launches 5 years later): led R&D and commercial teams, started tri-therapy trials ahead of individual approval, pursued assets covering all genotypes - Led new Kaletra HIV campaign that turned around market share globally (stabilized to +2%) despite competitors new launches

Doubled Abbott Denmark sales in 2 years and transformed culture into highly entrepreneurial: launched first 3 Humira indications, maximized the rest of portfolio, won “Great Place to Work” award, turnaround story told in “Innovation as Usual” Harvard BR Press book

Led key products marketing across Europe (Clarithromycin, Reductil, Sevo, Zemplar), developed and rolled out marketing excellence program across the whole Region